# Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV

> **NCT06782685** · PHASE1,PHASE2 · RECRUITING · sponsor: **Dai, Guanghai** · enrollment: 138 (estimated)

## Conditions studied

- Advanced Pancreatic Cancer (Part 1)

## Interventions

- **DRUG:** Irinotecan liposoma
- **DRUG:** oxaliplatin
- **DRUG:** bevacizumab
- **DRUG:** 5-FU
- **DRUG:** LV
- **DRUG:** Irinotecan Liposomal
- **DRUG:** Irinotecan Liposomal
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT06782685
- **Lead sponsor:** Dai, Guanghai
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-23
- **Primary completion:** 2026-07
- **Final completion:** 2027-03
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2025-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06782685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06782685, "Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06782685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*